Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc

Jun 18 • 04:00PM ET

27.44

+0.53 1.97 %

Healthcare • Biotechnology • USA • Mid • NASD

Jun 17, 10:01 AMGoldman Sachs gene therapy spotlight and FDA guidance drive Ultragenyx 8% gain

Peers: BMRN RYTM KRYS MIRM PTCT IONS ALNY INCY VRTX KOD

| Held by: XBI VTI VB VBK VXF IBB IWP SCHA IWR IWF

Index	-	P/E	-	EPS (ttm)	-6.11	Insider Own	8.96%	Shs Outstand	98.00M	Perf Week	14.43%
Market Cap	2.70B	Forward P/E	-	EPS next Y	-0.70	Insider Trans	-1.58%	Shs Float	89.67M	Perf Month	22.23%
Enterprise Value	3.49B	PEG	-	EPS next Q	-1.22	Inst Own	97.72%	Short Float	16.40%	Perf Quarter	34.38%
Income	-609.36M	P/S	4.04	EPS this Y	23.11%	Inst Trans	4.73%	Short Ratio	7.95	Perf Half Y	-20.09%
Sales	669.43M	P/B	-	EPS next Y	84.40%	ROA	-46.73%	Short Interest	14.70M	Perf YTD	19.30%
Book/sh	-2.41	P/C	6.42	EPS next 5Y	-	ROE	-656.54%	52W High	42.37 -35.24%	Perf Year	-26.53%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	16.78% -13.72%	ROIC	-68.31%	52W Low	18.29 50.03%	Perf 3Y	-43.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.81% 19.95%	Gross Margin	78.49%	Volatility	5.20% 4.88%	Perf 5Y	-71.09%
Dividend TTM	-	EV/Sales	5.21	EPS Y/Y TTM	-3.82%	Oper. Margin	-83.92%	ATR (14)	1.27	Perf 10Y	-50.10%
Dividend Ex-Date	-	Quick Ratio	1.85	Sales Y/Y TTM	13.33%	Profit Margin	-91.03%	RSI (14)	66.71	Recom	1.32
Dividend Gr. 3/5Y	- -	Current Ratio	2.02	EPS Q/Q	-17.21%	SMA20	15.94%	Beta	0.34	Target Price	52.05
Payout	-	Debt/Eq	-	Sales Q/Q	-2.36%	SMA50	12.83%	Rel Volume	1.93	Prev Close	26.91
Employees	1371	LT Debt/Eq	-	Earnings	May 05 AMC	SMA200	1.51%	Avg Volume	1.85M	Price	27.44
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.67% -14.03%	Trades		Volume	3,562,375	Change	1.97%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-26	Downgrade	Goldman	Buy → Neutral	$25
Oct-20-25	Initiated	Wells Fargo	Overweight	$65
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral

Show Previous Ratings

Jun-03-26 04:30PM	Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-22-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-26 04:30PM	Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference (GlobeNewswire)
08:30AM	Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary (Moby)
May-05-26 04:07PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-29-26 08:00AM	Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-24-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:30AM	Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Mar-30-26 08:30AM	Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy (GlobeNewswire)
03:41AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-24-26 09:36AM	Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls (The Fly) -8.73%
Mar-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-26 06:17AM	Evotec, Vistagen lay off staff; Immutep shares collapse on study failure (BioPharma Dive)
Mar-12-26 08:30AM	Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency (GlobeNewswire)
04:18AM	Loading…
04:18AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-11-26 09:00AM	LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Mar-04-26 09:00AM	LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE (PR Newswire)
Feb-25-26 09:00AM	LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Feb-24-26 10:19AM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Feb-23-26 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
08:30AM	Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Feb-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 12:23PM	Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) (Insider Monkey)
Feb-14-26 01:29AM	Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A (Insider Monkey)
Feb-13-26 01:21PM	Why Is Ultragenyx Stock Sinking Friday? (Benzinga) -12.68%
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
08:30AM	Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary (Moby)
05:08AM	Ultragenyx cuts jobs as it seeks path to profit in 2027 (BioPharma Dive)
12:02AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
08:14PM	Loading…
Feb-12-26 08:14PM	Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:18PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
Feb-09-26 03:30AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Feb-07-26 03:33AM	Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment (Insider Monkey)
Feb-06-26 07:40AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights RARE (Business Wire)
Feb-05-26 04:05PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-03-26 12:58PM	Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder (Benzinga)
08:00AM	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
Jan-30-26 08:30AM	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA (GlobeNewswire)
Jan-23-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:05PM	Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies (PR Newswire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-12-26 10:11AM	Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery (Insider Monkey) +8.26%
07:30AM	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Analysts Lower Ultragenyx (RARE) Target but Stay Bullish (Insider Monkey)
Jan-07-26 04:05PM	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.36%
Jan-05-26 03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks)
09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
07:37AM	Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall (Insider Monkey)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart) +15.52%
04:05PM	Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
03:58PM	Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today (Motley Fool)
12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
08:11AM	Company News for Dec 30, 2025 (Zacks)
06:17AM	S&P Futures Tread Water Ahead of FOMC Meeting Minutes (Barchart)
Dec-29-25 04:21PM	These Stocks Moved the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com) -42.32%
03:34PM	Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today (Motley Fool)
01:18PM	These Stocks Are Moving the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com)
01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch)
08:30AM	Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Dec-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 07:44AM	Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Dec-04-25 11:30AM	Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-28-25 11:57AM	Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook (Insider Monkey)
Nov-24-25 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-21-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Nov-10-25 08:19PM	Morgan Stanley Reaffirms "Buy" Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
12:10AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 05:30PM	Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
04:01PM	Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences (GlobeNewswire)
Oct-30-25 08:00AM	Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups (GlobeNewswire)
Oct-29-25 10:00AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-28-25 04:30PM	Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-24-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
Oct-17-25 09:16AM	Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Oct-08-25 12:57AM	Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Oct-03-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 09:45AM	Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline (Insider Monkey)
Sep-30-25 04:05PM	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President (GlobeNewswire)
04:00AM	Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Sep-29-25 08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
Sep-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 09:17AM	Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity? (Insider Monkey)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ph.D.Dr. Emil D. Kakkis M.D.

Executive VP of Corporate Strategy & CFOMr. Howard Horn

Chief Legal Officer & Executive VP of Corporate AffairsMs. Karah Herdman Parschauer J.D.

Executive VP & Chief Commercial OfficerMr. Erik Harris M.B.A.

Chief Medical Officer & Executive VPDr. Eric Crombez M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanders Corazon (Corsee) D.	Director	Jun 15 '26	Sale	25.05	2,000	50,100	21,095	Jun 15 06:50 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Jun 15 '26	Sale	24.62	1,899	46,753	94,462	Jun 15 06:46 PM
KARAH PARSCHAUER	Officer	Jun 15 '26	Proposed Sale	24.35	3,799	92,506		Jun 15 04:50 PM
CORAZON D. SANDERS	Director	Jun 15 '26	Proposed Sale	25.05	2,000	50,100		Jun 15 04:12 PM
Horn Howard	Chief Financial Officer	Jun 01 '26	Sale	23.77	4,653	110,602	105,689	Jun 01 07:11 PM
HOWARD HORN	Officer	Jun 01 '26	Proposed Sale	23.77	4,653	110,602		Jun 01 04:08 PM
SULIMAN SHEHNAAZ	Director	May 18 '26	Sale	25.12	5,740	144,189	27,951	May 18 06:41 PM
SHEHNAAZ SULIMAN	Director	May 18 '26	Proposed Sale	25.12	5,740	144,189		May 18 04:50 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '26	Sale	24.96	344	8,586	111,189	May 06 02:51 PM
Horn Howard	Chief Financial Officer	May 01 '26	Sale	24.90	4,683	116,607	110,342	May 04 05:35 PM
HOWARD HORN	Officer	May 01 '26	Proposed Sale	24.90	4,683	116,607		May 01 04:06 PM
Horn Howard	Chief Financial Officer	Apr 01 '26	Sale	20.97	4,683	98,203	80,351	Apr 02 06:19 PM
HOWARD HORN	Officer	Apr 01 '26	Proposed Sale	20.97	4,683	98,203		Apr 01 04:12 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 06 '26	Sale	21.40	6,018	128,785	70,328	Mar 10 04:51 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 10 '26	Sale	22.67	3,508	79,526	66,820	Mar 10 04:51 PM
KARAH PARSCHAUER	Officer	Mar 10 '26	Proposed Sale	22.67	3,508	79,526		Mar 10 04:42 PM
KARAH PARSCHAUER	Officer	Mar 06 '26	Proposed Sale	21.40	6,018	128,775		Mar 06 05:28 PM
Pinion John Richard	See Remarks	Mar 02 '26	Sale	22.80	10,029	228,661	110,026	Mar 03 07:09 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 02 '26	Sale	22.80	10,539	240,289	89,515	Mar 03 07:08 PM
KAKKIS EMIL D	President & CEO	Mar 02 '26	Sale	22.80	54,404	1,240,411	658,994	Mar 03 07:06 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 02 '26	Sale	22.80	8,135	185,478	76,346	Mar 03 06:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 02 '26	Sale	22.80	1,632	37,210	48,670	Mar 03 06:51 PM
Horn Howard	Chief Financial Officer	Mar 02 '26	Sale	22.70	8,409	190,914	86,669	Mar 03 06:50 PM
Horn Howard	Chief Financial Officer	Mar 03 '26	Sale	22.40	1,635	36,624	85,034	Mar 03 06:50 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 02 '26	Sale	22.80	7,029	160,261	76,301	Mar 03 06:49 PM
HOWARD HORN	Officer	Mar 03 '26	Proposed Sale	22.40	1,635	36,624		Mar 03 04:41 PM
HOWARD HORN	Officer	Mar 02 '26	Proposed Sale	22.54	3,119	70,302		Mar 02 05:08 PM
Horn Howard	Chief Financial Officer	Feb 02 '26	Sale	23.56	3,061	72,117	88,935	Feb 03 12:00 PM
HOWARD HORN	Officer	Feb 02 '26	Proposed Sale	23.56	3,061	72,117		Feb 02 04:09 PM
Horn Howard	Chief Financial Officer	Jan 02 '26	Sale	22.84	3,150	71,946	91,996	Jan 05 04:07 PM
HOWARD HORN	Officer	Jan 02 '26	Proposed Sale	22.84	3,150	71,946		Jan 02 04:10 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Dec 29 '25	Sale	34.38	85	2,922	50,450	Dec 30 01:49 PM
Horn Howard	Chief Financial Officer	Dec 10 '25	Sale	36.38	3,081	112,087	95,146	Dec 11 12:10 PM
HOWARD HORN	Officer	Dec 10 '25	Proposed Sale	36.38	3,081	112,087		Dec 10 04:05 PM
Horn Howard	Chief Financial Officer	Oct 13 '25	Sale	31.51	7,942	250,252	98,227	Oct 14 12:15 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 18 '25	Sale	29.17	64	1,867	50,242	Sep 19 06:23 PM
KARAH PARSCHAUER	Officer	Sep 12 '25	Proposed Sale	31.17	2,450	76,366		Sep 12 04:17 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Sep 12 '25	Sale	31.17	2,450	76,366	73,271	Sep 12 04:11 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 05 '25	Sale	31.39	84	2,637	50,306	Sep 08 02:01 PM
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM

Open in Screener

ONC

BeOne Medicines Ltd ADR

Jun 18 • 04:00PM ET

270.15

+7.47 2.84 %

Healthcare • Biotechnology • Switzerland • Large • NASD

ONC BeOne Medicines Ltd ADR daily Stock Chart

Peers: REGN VRTX AMGN GILD BIIB ALNY ARGX BMRN ABBV LLY

| Held by: IBB FBT CGGE BBH CGIE CGNG EMEQ CANC DFAE AVEM

Index	-	P/E	60.28	EPS (ttm)	4.48	Insider Own	0.52%	Shs Outstand	102.26M	Perf Week	3.80%
Market Cap	27.64B	Forward P/E	28.11	EPS next Y	9.61	Insider Trans	-6.23%	Shs Float	101.77M	Perf Month	-9.04%
Enterprise Value	24.86B	PEG	0.40	EPS next Q	1.65	Inst Own	33.69%	Short Float	1.07%	Perf Quarter	-4.45%
Income	514.49M	P/S	4.80	EPS this Y	155.94%	Inst Trans	-1.67%	Short Ratio	4.51	Perf Half Y	-11.23%
Sales	5.76B	P/B	6.31	EPS next Y	42.77%	ROA	7.15%	Short Interest	1.09M	Perf YTD	-11.08%
Book/sh	42.84	P/C	5.72	EPS next 5Y	70.60%	ROE	12.46%	52W High	385.22 -29.87%	Perf Year	6.87%
Cash/sh	47.24	P/FCF	24.73	EPS past 3/5Y	- -	ROIC	7.79%	52W Low	239.25 12.92%	Perf 3Y	34.93%
Dividend Est.	-	EV/EBITDA	29.64	Sales past 3/5Y	55.88% 76.88%	Gross Margin	86.15%	Volatility	2.72% 2.66%	Perf 5Y	-16.05%
Dividend TTM	-	EV/Sales	4.32	EPS Y/Y TTM	225.57%	Oper. Margin	11.95%	ATR (14)	8.24	Perf 10Y	768.65%
Dividend Ex-Date	-	Quick Ratio	3.27	Sales Y/Y TTM	37.70%	Profit Margin	8.94%	RSI (14)	41.11	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.64	EPS Q/Q	17028.70%	SMA20	-3.11%	Beta	0.51	Target Price	414.15
Payout	0.00%	Debt/Eq	0.43	Sales Q/Q	35.67%	SMA50	-8.59%	Rel Volume	1.51	Prev Close	262.68
Employees	12000	LT Debt/Eq	0.39	Earnings	May 06 BMO	SMA200	-15.14%	Avg Volume	241.32K	Price	270.15
IPO	Feb 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.38% 2.51%	Trades		Volume	365,063	Change	2.84%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	Wolfe Research	Outperform	$340
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$290
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Barclays	Overweight	$385
Apr-07-25	Initiated	RBC Capital Mkts	Outperform	$312
Mar-03-25	Upgrade	BofA Securities	Neutral → Buy	$207 → $320
Dec-03-24	Resumed	Morgan Stanley	Overweight	$300
Sep-18-24	Initiated	JMP Securities	Mkt Outperform	$288
Feb-06-24	Resumed	JP Morgan	Overweight	$185
Sep-12-23	Initiated	Macquarie	Outperform	$259
Aug-17-23	Initiated	Jefferies	Buy	$287
Jul-17-23	Initiated	Citigroup	Buy	$275
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform	$335 → $196
Jan-12-23	Initiated	Daiwa Securities	Buy	$308
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$177 → $200
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$205
Aug-09-22	Resumed	JP Morgan	Overweight	$296
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$300 → $177
Feb-07-22	Initiated	Deutsche Bank	Buy
Oct-12-21	Initiated	Bernstein	Outperform	$431

Show Previous Ratings

Jun-11-26 07:24AM	BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit (Business Wire)
Jun-01-26 06:00AM	BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 (Business Wire)
May-29-26 06:00AM	BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026 (Business Wire)
May-27-26 05:00PM	BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 (Business Wire)
May-26-26 06:01AM	BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
06:00AM	Loading…
May-21-26 06:00AM	BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts (Business Wire)
May-13-26 01:27PM	BeOne Medicines BEQALZI (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma (Business Wire)
May-06-26 06:00AM	BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates (Business Wire) +5.32%
May-04-26 09:43AM	AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls (The Fly)
Apr-29-26 06:00AM	U.S. FDA Grants Priority Review to BeOne Medicines TEVIMBRA in First-Line HER2+ GEA (Business Wire)
Apr-22-26 06:01AM	BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6 (Business Wire)
Mar-03-26 08:02PM	BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion (GuruFocus.com) -5.51%
Mar-01-26 09:59AM	BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment (Insider Monkey)
Feb-26-26 09:30AM	Here's What Key Metrics Tell Us About BeOne Medicines Ltd. - Sponsored ADR (ONC) Q4 Earnings (Zacks) -8.48%
06:00AM	BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership (Business Wire)
06:00AM	Loading…
Feb-17-26 06:00AM	BeOne Medicines to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 05:19AM	Bernstein Remains a Buy on BeOne Medicines AG (ONC) (Insider Monkey)
Feb-11-26 06:00AM	BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26 (Business Wire)
Feb-02-26 03:10AM	3 Stocks to Buy in February (Motley Fool)
Jan-31-26 09:36AM	Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development (Insider Monkey)
Jan-30-26 02:07AM	Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 (Insider Monkey)
Jan-29-26 12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
Jan-13-26 06:00AM	BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +5.11%
Jan-07-26 10:22AM	Is the Options Market Predicting a Spike in BeOne Medicines Stock? (Zacks)
Jan-06-26 01:30PM	ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA (Business Wire)
Dec-31-25 08:51AM	Strong Momentum Lifted BeOne Medicines AG (ONC) in Q3 (Insider Monkey)
Dec-23-25 06:01AM	BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 06:00AM	BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma (Business Wire)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
Dec-08-25 08:00AM	BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Nave Chronic Lymphocytic Leukemia (Business Wire)
06:00PM	Loading…
Dec-07-25 06:00PM	Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily)
Nov-21-25 12:59PM	This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452% (Investor's Business Daily)
Nov-20-25 06:00AM	BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 (Business Wire)
Nov-17-25 08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Positive Phase 3 Results Support ZIIHERA as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (Business Wire)
Nov-12-25 04:39PM	Stock Market Today: Dow Hits New Highs; Lilly, Barrick, Goldman Break Out (Live Coverage) (Investor's Business Daily) +9.84%
04:30PM	BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
01:19PM	BeOne Medicines Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
12:55PM	IBD Stock Of The Day BeOne Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
10:31AM	Stock Market Today: Dow Rises But Nasdaq Cools Again As Nvidia, AMD Rally (Live Coverage) (Investor's Business Daily)
Nov-11-25 12:07PM	Biotech Leader BeOne Medicines Eyes New Buy Point As Cancer Drug Sales Surge (Investor's Business Daily)
Nov-10-25 08:03PM	BeOne Medicines Ltd (ONC) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Nov-06-25 11:30AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:00AM	BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates (Business Wire)
Oct-28-25 06:01AM	BeOne Medicines to Present at Upcoming Investor Conferences (Business Wire)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks)
Oct-20-25 06:00AM	BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 (Business Wire)
Oct-13-25 06:00AM	BeOne Medicines Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA (Business Wire)
Oct-03-25 04:21PM	How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)
Oct-02-25 01:35AM	BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts (Insider Monkey)
Sep-29-25 10:35AM	Here's Why BeOne Medicines Ltd. (ONC) Declined in Q2 (Insider Monkey)
Sep-18-25 03:00AM	China's Young Consumers Set the Global Trend. What They're Buying Now. (Barrons.com)
Sep-14-25 01:16AM	Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC) (Insider Monkey)
Sep-12-25 01:01AM	BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL (Insider Monkey)
Sep-10-25 03:55PM	China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order (Investor's Business Daily) -10.59%
Aug-29-25 06:00AM	BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) (Business Wire)
Aug-28-25 04:55AM	BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025 (Insider Monkey)
Aug-27-25 06:00AM	European Commission Approves TEVIMBRA as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 (Business Wire)
Aug-26-25 06:01AM	BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-21-25 06:00AM	European Commission Approves Tablet Formulation of BeOne Medicines BRUKINSA for All Approved Indications (Business Wire)
Aug-15-25 12:55PM	This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth (Investor's Business Daily)
10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
Aug-08-25 12:44PM	Hims Stock Gets Booted Off IBD 50 While Other Volatile Names Hang On (Investor's Business Daily)
Aug-06-25 11:30AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
06:00AM	BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates (Business Wire)
Jul-31-25 06:00AM	BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstroms Macroglobulinemia (Business Wire)
Jul-28-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA in Neoadjuvant/Adjuvant NSCLC Treatment (Business Wire)
Jul-25-25 10:44PM	BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra (Insider Monkey)
10:06AM	Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Jul-18-25 03:43PM	The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New Highs (Investor's Business Daily)
10:06AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains? (Zacks)
Jul-16-25 12:58PM	Looming Tariffs Don't Scare This Swiss Cancer Treatment Stock (Investor's Business Daily)
06:00AM	BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jul-10-25 06:00AM	European Commission Approves TEVIMBRA in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma (Business Wire)
Jun-28-25 08:35AM	BeOne Medicines price target raised to $330 from $313 at Morgan Stanley (TipRanks)
Jun-26-25 06:00AM	BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day (Business Wire)
Jun-25-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA (Business Wire)
Jun-12-25 06:00AM	BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 (Business Wire) +5.38%
Jun-11-25 04:05PM	U.S. FDA Approves Tablet Formulation of BeOnes BRUKINSA for All Approved Indications (Business Wire)
06:01AM	BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 (Business Wire)
Jun-05-25 02:03PM	Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple (Investor's Business Daily)
Jun-02-25 06:00AM	BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 (Business Wire)
May-31-25 08:00AM	BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSAs Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025 (Business Wire)
May-27-25 08:30AM	BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology (Business Wire)
06:00AM	BeiGene Receives Positive CHMP Opinion for TEVIMBRA as a First-Line Treatment for Nasopharyngeal Cancer (Business Wire)
May-22-25 06:00AM	BeiGene Presents Pioneering Cancer Research at ASCO 2025 Redefining Treatment Across Hematology and Solid Tumors (Business Wire)
May-14-25 04:05PM	BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSAs Leadership and Next-Generation Innovation (Business Wire)
May-13-25 06:01AM	BeiGene to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-12-25 07:33AM	Trumps Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks (The Wall Street Journal)
12:05AM	Trump Drug Plan Hits Pharma Stocks (The Wall Street Journal)
12:05AM	Trump Drug Plan Hits Asian Pharma Stocks (The Wall Street Journal)
May-09-25 07:52AM	BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang's Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 01:00PM	BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ... (GuruFocus.com)
May-07-25 02:05PM	BeiGene targets $4.9B-$5.3B revenue for 2025 with strong BRUKINSA and pipeline growth (Seeking Alpha)
02:04PM	BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics (Zacks)
06:00AM	BeiGene Announces First Quarter 2025 Financial Results and Business Updates (Business Wire)
Apr-29-25 03:32PM	U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene (Business Wire)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Co-FounderMr. John V. Oyler

President and Global Head of Research & DevelopmentMr. Wang Lai Ph.D.

Co-Chairman of Scientific Advisory BoardDr. Xiaodong Wang Ph.D.

Chief Financial OfficerMr. Aaron Rosenberg

General CounselMr. Chan Lee

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wu Xiaobin	President and COO	Jun 16 '26	Sale	266.76	1,357	361,997	0	Jun 18 05:19 PM
OYLER JOHN	Chief Executive Officer	Jun 16 '26	Sale	265.55	3,693	980,686	0	Jun 18 05:19 PM
Lee Chan Henry	SVP, General Counsel	Jun 16 '26	Sale	265.98	590	156,925	0	Jun 18 05:19 PM
Wang Lai	President, Global Head of R&D	Jun 16 '26	Sale	265.39	1,169	310,236	0	Jun 18 05:19 PM
CHAN LEE	Officer	Jun 16 '26	Proposed Sale	265.98	590	156,925		Jun 16 04:15 PM
LAI WANG	Officer	Jun 16 '26	Proposed Sale	265.39	1,169	310,236		Jun 16 04:14 PM
XIAOBIN WU	Officer	Jun 16 '26	Proposed Sale	266.76	1,357	361,997		Jun 16 04:12 PM
JOHN OYLER	Officer	Jun 16 '26	Proposed Sale	265.55	3,693	980,686		Jun 16 04:11 PM
Ball Titus B.	Principal Accounting Officer	Jun 11 '26	Sale	257.20	169	43,467	0	Jun 15 05:55 PM
Wang Lai	President, Global Head of R&D	Jun 11 '26	Sale	261.00	756	197,318	0	Jun 15 05:55 PM
Rosenberg Aaron	Chief Financial Officer	Jun 11 '26	Sale	257.74	631	162,637	0	Jun 15 05:55 PM
Wu Xiaobin	President and COO	Jun 11 '26	Sale	261.20	626	163,512	0	Jun 15 05:55 PM
Lee Chan Henry	SVP, General Counsel	Jun 11 '26	Sale	257.63	428	110,268	0	Jun 15 05:55 PM
OYLER JOHN	Chief Executive Officer	Jun 11 '26	Sale	257.24	1,949	501,355	0	Jun 15 05:55 PM
CORAZON D. SANDERS	Director	Jun 15 '26	Proposed Sale	265.50	945	250,894		Jun 15 04:21 PM
XIAOBIN WU	Officer	Jun 11 '26	Proposed Sale	261.20	626	163,512		Jun 11 04:32 PM
LAI WANG	Officer	Jun 11 '26	Proposed Sale	261.41	756	197,630		Jun 11 04:29 PM
AARON ROSENBERG	Officer	Jun 11 '26	Proposed Sale	257.74	631	162,637		Jun 11 04:25 PM
TITUS BENJAMIN BALL	Officer	Jun 11 '26	Proposed Sale	257.20	169	43,467		Jun 11 04:24 PM
CHAN LEE	Officer	Jun 11 '26	Proposed Sale	257.63	428	110,268		Jun 11 04:23 PM
JOHN OYLER	Officer	Jun 11 '26	Proposed Sale	257.24	1,949	501,355		Jun 11 04:23 PM
Ball Titus B.	Principal Accounting Officer	Jun 08 '26	Sale	271.33	136	36,901	0	Jun 10 05:27 PM
Lee Chan Henry	SVP, General Counsel	Jun 08 '26	Sale	270.42	871	235,539	0	Jun 10 05:26 PM
Wang Lai	President, Global Head of R&D	Jun 08 '26	Sale	269.38	1,367	368,247	0	Jun 10 05:25 PM
Wu Xiaobin	President and COO	Jun 08 '26	Sale	269.37	1,484	399,738	0	Jun 10 05:23 PM
OYLER JOHN	Chief Executive Officer	Jun 08 '26	Sale	270.56	4,940	1,336,548	0	Jun 10 05:22 PM
TITUS BENJAMIN BALL	Officer	Jun 08 '26	Proposed Sale	271.33	136	36,901		Jun 08 04:31 PM
CHAN LEE	Officer	Jun 08 '26	Proposed Sale	270.42	871	235,539		Jun 08 04:29 PM
LAI WANG	Officer	Jun 08 '26	Proposed Sale	269.38	1,367	368,247		Jun 08 04:28 PM
XIAOBIN WU	Officer	Jun 08 '26	Proposed Sale	269.37	1,484	399,738		Jun 08 04:23 PM
JOHN OYLER	Officer	Jun 08 '26	Proposed Sale	270.56	4,940	1,336,548		Jun 08 04:18 PM
Yi Qingqing	Director	Jun 01 '26	Sale	279.13	235	65,596	0	Jun 03 04:10 PM
QINGQING YI	Director	Jun 01 '26	Proposed Sale	279.13	235	65,596		Jun 01 04:27 PM
Riva Alessandro	Director	May 22 '26	Sale	309.51	212	65,617	0	May 27 05:29 PM
Dugan Margaret	Director	May 22 '26	Sale	309.60	212	65,636	0	May 27 05:26 PM
Sanders Corazon (Corsee) D.	Director	May 22 '26	Sale	309.59	212	65,633	0	May 27 05:26 PM
BAKER BROS. ADVISORS LP	Director	May 22 '26	Sale	23.82	10,998	261,981	142,566	May 27 04:54 PM
MICHAEL GOLLER	Director	May 22 '26	Proposed Sale	310.07	211	65,424		May 22 04:28 PM
RANJEEV KRISHANA	Director	May 22 '26	Proposed Sale	309.28	212	65,567		May 22 04:25 PM
ALESSANDRO RIVA	Director	May 22 '26	Proposed Sale	309.51	212	65,617		May 22 04:22 PM
MARGARET DUGAN	Director	May 22 '26	Proposed Sale	309.60	212	65,636		May 22 04:20 PM
CORAZON D. SANDERS	Director	May 22 '26	Proposed Sale	309.59	212	65,633		May 22 04:18 PM
Lee Chan Henry	SVP, General Counsel	May 13 '26	Option Exercise	191.56	332	63,598	332	May 15 04:39 PM
Lee Chan Henry	SVP, General Counsel	May 13 '26	Sale	310.72	332	103,159	0	May 15 04:39 PM
CHAN LEE	Officer	May 13 '26	Proposed Sale	315.07	1,328	418,413		May 13 04:27 PM
Lee Chan Henry	SVP, General Counsel	Apr 08 '26	Option Exercise	191.56	332	63,598	332	Apr 10 05:40 PM
Lee Chan Henry	SVP, General Counsel	Apr 08 '26	Sale	311.59	332	103,448	0	Apr 10 05:40 PM
Lee Chan Henry	SVP, General Counsel	Mar 11 '26	Option Exercise	191.64	341	65,348	341	Mar 13 05:26 PM
Lee Chan Henry	SVP, General Counsel	Mar 11 '26	Sale	300.00	341	102,300	0	Mar 13 05:26 PM
Lee Chan Henry	SVP, General Counsel	Feb 04 '26	Option Exercise	191.40	1,660	317,721	1,660	Feb 06 04:57 PM
Lee Chan Henry	SVP, General Counsel	Feb 04 '26	Sale	349.52	1,660	580,197	0	Feb 06 04:57 PM
CHAN LEE	Officer	Feb 04 '26	Proposed Sale	346.38	4,676	1,619,673		Feb 04 04:21 PM
Lee Chan Henry	SVP, General Counsel	Jan 07 '26	Option Exercise	191.56	664	127,196	664	Jan 09 05:15 PM
Lee Chan Henry	SVP, General Counsel	Jan 07 '26	Sale	331.76	664	220,289	0	Jan 09 05:15 PM
OYLER JOHN	Chief Executive Officer	Dec 15 '25	Sale	307.79	75,631	23,278,679	24,369	Dec 17 04:47 PM
OYLER JOHN	Chief Executive Officer	Dec 16 '25	Sale	302.87	24,369	7,380,739	0	Dec 17 04:47 PM
JOHN V OYLER	Director	Dec 15 '25	Proposed Sale	319.06	100,000	31,906,000		Dec 15 04:32 PM
Lee Chan Henry	SVP, General Counsel	Dec 10 '25	Option Exercise	191.56	332	63,598	332	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 11 '25	Option Exercise	191.56	332	63,598	332	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 11 '25	Sale	325.00	332	107,900	0	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 10 '25	Sale	318.28	332	105,669	0	Dec 12 04:56 PM
Sanders Corazon (Corsee) D.	Director	Nov 26 '25	Option Exercise	159.03	2,627	417,772	2,627	Dec 01 04:57 PM
Sanders Corazon (Corsee) D.	Director	Nov 26 '25	Sale	340.90	2,627	895,534	0	Dec 01 04:57 PM
CORAZON D. SANDERS	Director	Nov 26 '25	Proposed Sale	340.90	2,627	895,535		Nov 26 04:13 PM
Wu Xiaobin	President and COO	Nov 17 '25	Sale	380.43	3,991	1,518,303	0	Nov 19 04:57 PM
XIAOBIN WU	Officer	Nov 17 '25	Proposed Sale	380.43	3,991	1,518,303		Nov 17 04:16 PM
Wu Xiaobin	President and COO	Nov 12 '25	Sale	356.02	10,000	3,560,161	6,009	Nov 14 05:35 PM
Wu Xiaobin	President and COO	Nov 13 '25	Sale	380.54	6,009	2,286,660	0	Nov 14 05:35 PM
Lee Chan Henry	SVP, General Counsel	Nov 12 '25	Option Exercise	191.47	996	190,704	996	Nov 14 05:28 PM
Lee Chan Henry	SVP, General Counsel	Nov 12 '25	Sale	349.17	996	347,770	0	Nov 14 05:28 PM
XIAOBIN WU	Officer	Nov 13 '25	Proposed Sale	380.54	6,009	2,286,659		Nov 13 04:22 PM
XIAOBIN WU	Officer	Nov 12 '25	Proposed Sale	356.02	10,000	3,560,161		Nov 12 05:04 PM
Lee Chan Henry	SVP, General Counsel	Oct 08 '25	Option Exercise	211.04	9,559	2,017,363	9,559	Oct 10 04:56 PM
Lee Chan Henry	SVP, General Counsel	Oct 08 '25	Sale	350.40	10,671	3,739,108	0	Oct 10 04:56 PM
CHAN LEE	Officer	Oct 08 '25	Proposed Sale	341.62	13,659	4,666,188		Oct 08 04:19 PM
OYLER JOHN	Chief Executive Officer	Sep 16 '25	Sale	325.71	27,803	9,055,694	0	Sep 18 04:45 PM
PAN-OYLER FOUNDATION	Director	Sep 16 '25	Proposed Sale	332.27	1,204	400,053		Sep 16 04:25 PM
JOHN V OYLER	Director	Sep 16 '25	Proposed Sale	332.27	27,803	9,238,103		Sep 16 04:22 PM
Lee Chan Henry	SVP, General Counsel	Sep 10 '25	Option Exercise	197.10	8,894	1,752,981	8,894	Sep 12 04:38 PM
Lee Chan Henry	SVP, General Counsel	Sep 10 '25	Sale	325.53	10,006	3,257,289	0	Sep 12 04:38 PM
Wang Lai	Global Head of R&D	Sep 09 '25	Sale	350.06	5,000	1,750,312	0	Sep 11 05:10 PM
CHAN LEE	Officer	Sep 10 '25	Proposed Sale	351.13	9,010	3,163,681		Sep 10 04:37 PM
Sanders Corazon (Corsee) D.	Director	Sep 05 '25	Option Exercise	155.68	2,665	414,887	2,665	Sep 09 05:31 PM
Sanders Corazon (Corsee) D.	Director	Sep 05 '25	Sale	337.00	2,665	898,105	0	Sep 09 05:31 PM
WANG HOLDINGS LLC	Officer	Sep 09 '25	Proposed Sale	346.45	5,000	1,732,250		Sep 09 04:28 PM
CORAZON D. SANDERS	Director	Sep 05 '25	Proposed Sale	337.00	2,665	898,105		Sep 05 04:02 PM
Ball Titus B.	Principal Accounting Officer	Sep 02 '25	Sale	326.76	122	39,865	0	Sep 04 05:29 PM
TITUS BENJAMIN BALL	Officer	Sep 02 '25	Proposed Sale	326.76	122	39,865		Sep 02 04:26 PM
Wu Xiaobin	President and COO	Aug 13 '25	Option Exercise	164.24	49,858	8,188,887	49,858	Aug 15 04:40 PM
Wu Xiaobin	President and COO	Aug 14 '25	Option Exercise	156.45	39,936	6,247,989	39,936	Aug 15 04:40 PM
Wu Xiaobin	President and COO	Aug 13 '25	Sale	304.16	49,858	15,164,818	0	Aug 15 04:40 PM
Wu Xiaobin	President and COO	Aug 14 '25	Sale	305.06	39,936	12,182,818	0	Aug 15 04:40 PM
Lee Chan Henry	SVP, General Counsel	Aug 13 '25	Option Exercise	177.90	8,230	1,464,080	8,230	Aug 15 04:38 PM
Lee Chan Henry	SVP, General Counsel	Aug 13 '25	Sale	300.45	11,013	3,308,877	0	Aug 15 04:38 PM
XIAOBIN WU	Officer	Aug 13 '25	Proposed Sale	288.10	89,794	25,869,651		Aug 13 04:30 PM
CHAN LEE	Officer	Aug 13 '25	Proposed Sale	288.10	10,338	2,978,378		Aug 13 04:28 PM
Rosenberg Aaron	Chief Financial Officer	Aug 01 '25	Sale	290.47	1,190	345,659	0	Aug 05 05:16 PM
AARON ROSENBERG	Officer	Aug 01 '25	Proposed Sale	290.47	1,190	345,659		Aug 01 04:21 PM
Wang Lai	Global Head of R&D	Jul 29 '25	Sale	302.49	4,041	1,222,380	259	Jul 31 05:05 PM
Wang Lai	Global Head of R&D	Jul 30 '25	Sale	305.00	259	78,995	0	Jul 31 05:05 PM

RARE

Ultragenyx Pharmaceutical Inc

ONC

BeOne Medicines Ltd ADR

Upgrade your Finviz experience